Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MELATONIN (MELATL07959)
MELATONIN · 1 trial · 1 indication
Difference in the average score of sleep quality
| Arm | Type | Description |
|---|---|---|
| Novanuit® Triple Action | EXPERIMENTAL | 2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime. |
| Name | Type | Description |
|---|---|---|
| MELATONIN (MELATL07959) | DRUG | Pharmaceutical form:Capsule Route of administration: Oral |
Inclusion criteria : * Healthy men or women volunteers, aged from 20 to 75 years included at the moment of the inclusion visit. * Subject with Body Mass Index (BMI) between 18.5 and 29.9 kg/m² (limits included). * Good general health (based on subject interview about his/her medical history and on ...
Top 2 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Vanda Pharmaceuticals Inc. | VNDA | 2 | PHASE3 | tasimelteon |
MELATONIN is being studied for sleep disorders. A Phase 1 trial evaluated improvements in sleep quality in healthy volunteers with sleep disorders. It is an investigational small molecule developed by Sanofi, and it is not described as an approved treatment.
MELATONIN targets the melatonin receptors MTNR1A and MTNR1B, where it acts as an agonist. By binding and activating these receptors, it is designed to influence sleep regulation, which is the basis for its study in sleep disorders.
MELATONIN is developed by Sanofi, which trades under the ticker SNY. Sanofi is the company associated with this investigational sleep disorder asset.
MELATONIN is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. It is an investigational small molecule and is not described as FDA approved.
MELATONIN has been studied in one completed Phase 1 trial, NCT03514732, titled a study to evaluate improvements of the quality of sleep with NOVANUIT Triple Action in healthy volunteers with sleep disorders. It enrolled 40 participants in Poland and was uncontrolled, with no randomization or blinding.
Yes, MELATONIN is also known as MELATONIN (MELATL07959). Both names refer to the same Sanofi investigational small molecule being studied for sleep disorders.